Results 191 to 200 of about 95,123 (282)

BRCA1 Is Required for Postreplication Repair after UV-Induced DNA Damage [PDF]

, 2011
Shailja Pathania, Jenna Nguyen, Sarah J. Hill, Ralph Scully, Guillaume Adelmant, Jarrod A. Marto, Jean Feunteun, David M. Livingston   +7 more
openalex   +1 more source

BRCA1 Gene [PDF]

, 2020
openaire   +1 more source

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, Volume 16, Issue 2, Page 432-446, February 2026.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort. [PDF]

Commun Med (Lond)
Al Assaad M, Hadi K, Levine MF, Guevara D, Patel M, Tranquille M, King A, Otilano J, Semaan A, Gundem G, Medina-Martínez JS, Sigouros M, Manohar J, Kuo HH, Wilkes DC, Andreopoulou E, Chapman-Davis E, Tagawa ST, Sboner A, Ocean AJ, Shah MA, Papaemmanuil E, Sternberg CN, Holcomb K, Nanus DM, Elemento O, Mosquera JM.   +26 more
europepmc   +1 more source

Sperm quality and fertility are compromised in brca1 mutant male mice [PDF]

, 2015
Robert Stobezki, Shiny Titus, B. Musul, F. Moy, Kutluk Oktay   +4 more
openalex   +1 more source

Survival outcomes in prostate cancer patients treated at an Indian tertiary care centre

BJUI Compass, Volume 7, Issue 2, February 2026.
Abstract Background Prostate cancer is an emerging public health concern in India, with rising incidence and varying survival outcomes. This study aimed to evaluate 5‐year overall survival and identify prognostic factors among prostate cancer patients treated at Tata Memorial Hospital (TMH), Mumbai.
Aswathy P, Sivaranjini Kannusamy, Amey Oak, Gagan Prakash, Amit Joshi, Vedang Murthy, Santosh Menon, Sandhya Cheulkar, Monika Lokhande, Ganesh Balasubramaniam, Rajesh Dikshit, Pankaj Chaturvedi, Sudeep Gupta   +12 more
wiley   +1 more source

Germline BRCA1/2 Variants in Polish Patients with Family History of Breast and Ovarian Cancer: Prevalence, CNV Detection, and Identification of a Novel Loss-of-Function Mutation. [PDF]

Curr Oncol
Skoczylas S, Płoszaj T, Dróżdż I, Moczulska H, Serafin M, Piekarska K, Wojtyczka O, Żeżawska K, Zmysłowska A.   +8 more
europepmc   +1 more source

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

, 2017
George Somlo, Paul Frankel, Banu Arun, X. Cynthia, Agustin A. García, Tessa Cigler, Leah Cream, Harold A. Harvey, Joseph A. Sparano, Rita Nanda, Helen K. Chew, Timothy J. Moynihan, Linda T. Vahdat, Matthew P. Goetz, Jan H. Beumer, Arti Hurria, Joanne Mortimer, Richard Piekarz, Sharon Sand, Josef Herzog, Lily R. Van Tongeren, Katherine V. Ferry‐Galow, Alice P. Chen, Christopher Ruel, Edward M. Newman, David R. Gandara, Jeffrey N. Weitzel   +26 more
openalex   +2 more sources

The BRCA1 suppressor hypothesis: An explanation for the tissue-specific tumor development in BRCA1 patients [PDF]

, 2002
Stephen J. Elledge, Angelika Amon
openalex   +1 more source

Breast Events After Treatment of Ductal Carcinoma In Situ in Women: A Population‐Based Study

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Despite favourable survival prognosis, the main concern for ductal carcinoma in situ (DCIS) is local recurrence, especially progression to invasive cancer. This study identified factors associated with breast events following DCIS treatment.
Qian Chen, Ian Campbell, Mark Elwood, Alana Cavadino, Phyu Sin Aye, Sandar Tin Tin   +5 more
wiley   +1 more source